Healthcare Companies Receive Analyst Rating Updates

Several healthcare companies have recently received analyst ratings updates from top financial institutions. Merck & Company (MRK) was upgraded to Buy by Morgan Stanley's Terence Flynn, who also set a price target of $179.00. The current consensus on the stock is Moderate Buy with an average price target of $160.40, representing a 9.1% upside from its current levels.

HSBC also maintained a Buy rating on MRK with a $172.00 price target in a report issued earlier this month. Flynn's upgrade comes after he maintained a Buy rating and set a price target of $179.00 for the company, which closed last Friday at $146.87.

Flynn has a 5-star analyst ranking on TipRanks.com with an average return of 9.7% and a success rate of 59.2%. He covers the Healthcare sector and focuses on stocks such as Structure Therapeutics, Inc. Sponsored ADR and Arvinas Holding Company.

On the other hand, Envista Holdings (NVST) received a Hold rating from Erin Wright at Morgan Stanley, who also set a price target of $23.00. The company's shares closed last Friday at $23.35. Wright has a 5-star analyst ranking on TipRanks.com with an average return of 14.4% and a success rate of 61.7%. She covers the Healthcare sector and focuses on stocks such as BrightSpring Health Services, Inc.

Ultragenyx Pharmaceutical (RARE) was also downgraded to Hold by Bank of America Securities' Tazeen Ahmad with a price target of $20.00. The company's shares closed last Friday at $14.51. Ahmad has a 4-star analyst ranking on TipRanks.com with an average return of 4.6% and a success rate of 56.8%. He covers the Healthcare sector and focuses on stocks such as Parabilis Medicines, Inc.